The historical rank and industry rank for Akebia Therapeutics's FCF Margin % or its related term are showing as below:
AKBA'
s FCF Margin % Range Over the Past 10 Years
Min: -119.55 Med: -28.64 Max: 3598.96
Current: 22.47
During the past 13 years, the highest FCF Margin % of Akebia Therapeutics was 3598.96%. The lowest was -119.55%. And the median was -28.64%.
AKBA's FCF Margin % is ranked better than 91.73% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs AKBA: 22.47
Akebia Therapeutics FCF Margin % Related Terms
Akebia Therapeutics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics (AKBA) has a FCF Margin % of -39.72% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Akebia Therapeutics and its competitors. According to the industry distribution chart, Akebia Therapeutics ranks #79 out of 955 companies in the Drug Manufacturers industry, placing it in the top 8.3%.
Is Akebia Therapeutics' FCF Margin % too high?
Akebia Therapeutics' current FCF Margin % is -39.72%. Based on the distribution chart, Akebia Therapeutics ranks #79 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Akebia Therapeutics has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' FCF Margin % compare to TKNO and ORGO?
According to the Drug Manufacturers industry distribution chart, Akebia Therapeutics ranks #79 out of 955 companies for FCF Margin %. This places Akebia Therapeutics in the top 8% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Akebia Therapeutics and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akebia Therapeutics's current FCF Margin % is -39.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (AKBA) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.31, compared to a current price of $1.14 — trading 13% below its estimated fair value. The current FCF Margin % is -39.72%. Akebia Therapeutics' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Akebia Therapeutics (AKBA), the current FCF Margin % is -39.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (AKBA) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued.
The current stock price of $1.14 is trading 13% below its estimated GF Value™ of $1.31.
GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.
Key valuation signals for AKBA:
FCF Margin %: -39.72%
GF Value™: $1.31 vs. price of $1.14 (13% below fair value)
No single metric tells the full story. See the AKBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
49GF Score
Get the complete analysis for AKBA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AKBA has been successfully added to your 
